Table 2.
Multivariate analyses for the factors associated with hepatocellular carcinoma and HBsAg seroclearance
| Variables | Adjusted HR | 95% CI | P-value* |
|---|---|---|---|
| Development of HCC | |||
| Age at HBeAg seroclearance | 1.045 | 0.990–1.103 | 0.111 |
| Male gender | 2.986 | 0.777–11.472 | 0.111 |
| Cirrhosis | 24.651 | 3.0128–201.365 | 0.017 |
| Detectable HBV DNA† at HBeAg seroclearance | 1.228 | 0.295–5.108 | 0.778 |
| Elevated ALT‡ at HBeAg seroclearance | 1.625 | 0.268–9.864 | 0.598 |
| Tenofovir (versus entecavir) | 0.868 | 0.233–3.237 | 0.833 |
| Achievement of HBsAg seroclearance | |||
| Age at HBeAg seroclearance | 1.037 | 0.995–1.082 | 0.086 |
| Male gender | 0.886 | 0.306–2.568 | 0.824 |
| Cirrhosis | 1.042 | 0.351–3.094 | 0.941 |
| Detectable HBV DNA† at HBeAg seroclearance | 0.980 | 0.264–3.639 | 0.976 |
| Elevated ALT‡ at HBeAg seroclearance | 2.169 | 0.501–9.397 | 0.301 |
| Tenofovir (versus entecavir) | 1.388 | 0.461–4.178 | 0.560 |
*P-value from logistic regression models
†The lower limit of detection for HBV DNA is 12 IU/mL
‡The upper limit of normal ALT level is less than 40 IU/L.
Abbreviations: HR hazard ratio; CI, confidence interval; HCC hepatocellular carcinoma; ALT alanine aminotransferase; HBV hepatitis B virus; HBeAg Hepatitis B e antigen; HBsAg Hepatitis B s antigen